Evidence map›Paper›PMID 24827579›Full record

ArticlePloS one2014

Transcriptome-based analysis of kidney gene expression changes associated with diabetes in OVE26 mice, in the presence and absence of losartan treatment.

Radko Komers, Bei Xu, Yi Fu, Aaron McClelland, Phillip Kantharidis, Amit Mittal, Herbert T Cohen, David M Cohen

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Podocyte-specific knockout of cyclooxygenase 2 exacerbates diabetic kidney disease.American journal of physiology. Renal physiology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Radko KomersDivision of Nephrology and Hypertension, Department of Medicine, Oregon Health & Science University, Portland, Oregon; Portland V. A. Medical Center, Portland, Oregon, United States of America.
Bei XuDivision of Nephrology and Hypertension, Department of Medicine, Oregon Health & Science University, Portland, Oregon; Portland V. A. Medical Center, Portland, Oregon, United States of America.
Yi FuDivision of Nephrology and Hypertension, Department of Medicine, Oregon Health & Science University, Portland, Oregon; Portland V. A. Medical Center, Portland, Oregon, United States of America.
Aaron McClellandJDRF Danielle Alberti Memorial Centre for Diabetes Complications, Diabetes Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia.
Phillip KantharidisJDRF Danielle Alberti Memorial Centre for Diabetes Complications, Diabetes Division, Baker IDI Heart and Diabetes Institute, Melbourne, Australia.
Amit MittalNephrology Section, Boston University School of Medicine, Boston, Massachusetts, United States of America.
Herbert T CohenNephrology Section, Boston University School of Medicine, Boston, Massachusetts, United States of America.
David M CohenDivision of Nephrology and Hypertension, Department of Medicine, Oregon Health & Science University, Portland, Oregon; Portland V. A. Medical Center, Portland, Oregon, United States of America.
Oregon Health & Science University · USBaker Heart and Diabetes Institute · AUBoston University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes is among the most common causes of end-stage renal disease, although its pathophysiology is incompletely understood. We performed next-generation sequencing-based transcriptome analysis of renal gene expression changes in the OVE26 murine model of diabetes (age 15 weeks), relative to non-diabetic control, in the presence and absence of short-term (seven-day) treatment with the angiotensin receptor blocker, losartan (n = 3-6 biological replicates per condition). We detected 1438 statistically significant changes in gene expression across conditions. Of the 638 genes dysregulated in diabetes relative to the non-diabetic state, >70% were downregulation events. Unbiased functional annotation of genes up- and down-regulated by diabetes strongly associated (p<1 × 10(-8)) with terms for oxidative stress and for endoplasmic reticulum stress/protein folding. Most of the individual gene products up- or down-regulated with diabetes were unaffected by losartan treatment; however, of the gene products dysregulated in diabetes and influenced by losartan treatment, the vast majority of changes were in the direction of amelioration rather than exacerbation of the diabetic dysregulation. This group of losartan-protected genes associated strongly with annotation terms for endoplasmic reticulum stress, heat shock proteins, and chaperone function, but not oxidative stress; therefore, the losartan-unaffected genes suggest avenues for additional therapeutic opportunity in diabetes. Interestingly, the gene product most highly upregulated by diabetes (>52-fold), encoded by the cationic amino acid transporter Slc7a12, and the gene product most highly downregulated by diabetes (>99%)--encoded by the "pseudogene" Gm6300--are adjacent in the murine genome, are members of the SLC7 gene family, and are likely paralogous. Therefore, diabetes activates a near-total genetic switch between these two paralogs. Other individual-level changes in gene expression are potentially relevant to diabetic pathophysiology, and novel pathways are suggested. Genes unaffected by diabetes alone but exhibiting increased renal expression with losartan produced a signature consistent with malignant potential.

Indexed as

Amino Acid Transport System y+Angiotensin Receptor AntagonistsAnimalsDiabetes Mellitus, Type 1Diabetic NephropathiesDisease Models, AnimalEndoplasmic Reticulum StressGene Expression ProfilingGene Expression RegulationHeat-Shock ProteinsKidneyLosartanMaleMiceMice, TransgenicMolecular ChaperonesAmino Acid Transport System y+Angiotensin Receptor AntagonistsHeat-Shock ProteinsLosartanMolecular ChaperonesSlc7a12 protein, mouse

Identifiers

PMID24827579
PMCPMC4020814
OpenAlexW2013550125

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.